Neurologist Dr. Leah Croll talks about the new research suggesting they might help in treating people with alcohol use ...

The rising use of glucagon-like peptide-1 (GLP ... of drug that mimics the glucagon-like peptide-1 hormone. It stimulates insulin secretion and reduces appetite, helping to control blood sugar and ...

For this study, researchers analyzed U.S. federal research data in which people were asked about their GLP-1 prescriptions. Results showed that among people without diabetes, GLP-1 drug use rose ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Novo Nordisk's GLP-1 receptor ... alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use for the versatile drug class. The small, 48-subject study ...

However, it is important to note that the study's cross-sectional design means these findings are correlational, not causal; the data do not show that these factors cause interest in GLP-1 use.

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

Scientists have been studying other possible health benefits of GLP-1s. Popular obesity and diabetes drugs called GLP-1 ... use disorder," Dr. Maurice O'Farrell, lead author of the study and ...

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter ... for Alzheimer’s disease prevention in the future. As use of these drugs ...

The rise of GLP-1 weight loss drugs represents a shift in the way consumers ... The Acosta Group study confirms the growing interest in GLP-1 products and shows how this therapeutic option has ...

(CNN) — The use of ... a new study finds, even though there’s little information on the drugs’ safety and effectiveness for the condition. The family of medications called GLP-1 receptor ...